ReviewNature reviews. Disease primers2017
Oesophageal cancer.
Review in Nature reviews. Disease primers, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 631 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
631 citing papers in PubMed, 8 syntheses or guidelines pooled it, 1,058 citations in OpenAlex.
- Pooled it
- The Role of PD-L1 Expression as a Predictive Biomarker in Esophageal Cancer: a Meta-Analysis.Journal of gastrointestinal cancer · 2026Pooled it
- Role of m5C methylation in digestive system tumors (Review).Molecular medicine reports · 2025Pooled it
- Pooled it
- Effects of Postoperative Complications on Overall Survival Following Esophagectomy: A Meta-Analysis Using the Restricted Mean Survival Time Analysis.Thoracic cancer · 2025Pooled it
- Saliva and blood miRNAs as complementary biomarkers for esophageal cancer detection.Frontiers in oncology · 2025Pooled it
- Research trends in neoadjuvant therapy for esophageal cancer: a bibliometric and meta-analysis.Frontiers in immunology · 2025Pooled it
- CT-based radiomics for predicting lymph node metastasis in esophageal cancer: a systematic review and meta-analysis.Frontiers in oncology · 2024Pooled it
- Health-related quality-of-life analysis from KEYNOTE-590: pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer.The oncologist · 2024Trial
- High Serum IgA Identifies Poor Responders to Immune Checkpoint Inhibitors in Patients with Unresectable Esophageal Squamous Cell Carcinoma.Annals of surgical oncology · 2026Article
- ASO Author Reflections: Serum IgA as a Predictive Biomarker for Immunotherapy in Esophageal Squamous Cell Carcinoma.Annals of surgical oncology · 2026Article
- Cancer treatment alters mutant selection in normal esophagus.Nature genetics · 2026Article
- Clinical Interchangeability of 22C3 and 28 - 8 PD-L1 assays for patient selection in esophageal squamous cell carcinoma.Virchows Archiv : an international journal of pathology · 2026Article
- Alcohol exposure promotes cell communication network 1 cleavage in esophageal adenocarcinoma cells exclusively.Journal of cell communication and signaling · 2026Article
- Lactylation Modification and Esophageal Cancer: Research Progress From Hypoxia-Induced Metabolic Reprogramming to Immune Escape.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Review
- Prognostic Value of Pretreatment [18F]FDG PET/CT Metabolic Parameters for Overall Survival in Esophageal Cancer: A Single-Center Retrospective Cohort with Long-Term Follow-Up.Diagnostics (Basel, Switzerland) · 2026Article
- Multi-omics integration and machine learning define an iron-sulfur cluster/zinc-binding protein prognostic signature in esophageal squamous cell carcinoma.Mammalian genome : official journal of the International Mammalian Genome Society · 2026Article
- Occult Esophageal Squamous Cell Carcinoma Presenting as Bone-Predominant Carcinoma of Unknown Primary: A Case Report of a p40-Negative Vertebral Metastasis.Diagnostics (Basel, Switzerland) · 2026Article
- FOXA2 suppresses ESCC proliferation and metastasis by inhibiting PSMB9 expression, thereby attenuating proteasome activity.Cancer cell international · 2026Article
- Design, Synthesis, and Antitumor Activities of Novel Coumarin-Based Histone Deacetylase Inhibitors.Biomolecules · 2026Article
571 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 6 institutions in 4 countries.
Funding
Abstract
Oesophageal cancer is the sixth most common cause of cancer-related death worldwide and is therefore a major global health challenge. The two major subtypes of oesophageal cancer are oesophageal squamous cell carcinoma (OSCC) and oesophageal adenocarcinoma (OAC), which are epidemiologically and biologically distinct. OSCC accounts for 90% of all cases of oesophageal cancer globally and is highly prevalent in the East, East Africa and South America. OAC is more common in developed countries than in developing countries. Preneoplastic lesions are identifiable for both OSCC and OAC; these are frequently amenable to endoscopic ablative therapies. Most patients with oesophageal cancer require extensive treatment, including chemotherapy, chemoradiotherapy and/or surgical resection. Patients with advanced or metastatic oesophageal cancer are treated with palliative chemotherapy; those who are human epidermal growth factor receptor 2 (HER2)-positive may also benefit from trastuzumab treatment. Immuno-oncology therapies have also shown promising early results in OSCC and OAC. In this Primer, we review state-of-the-art knowledge on the biology and treatment of oesophageal cancer, including screening, endoscopic ablative therapies and emerging molecular targets, and we discuss best practices in chemotherapy, chemoradiotherapy, surgery and the maintenance of patient quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.